388 related articles for article (PubMed ID: 18223214)
1. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Baskar S; Kwong KY; Hofer T; Levy JM; Kennedy MG; Lee E; Staudt LM; Wilson WH; Wiestner A; Rader C
Clin Cancer Res; 2008 Jan; 14(2):396-404. PubMed ID: 18223214
[TBL] [Abstract][Full Text] [Related]
2. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.
Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Int J Cancer; 2008 Sep; 123(5):1190-5. PubMed ID: 18546292
[TBL] [Abstract][Full Text] [Related]
3. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
PLoS One; 2015; 10(11):e0142310. PubMed ID: 26562161
[TBL] [Abstract][Full Text] [Related]
5. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
[TBL] [Abstract][Full Text] [Related]
6. Post-translational modifications regulate signalling by Ror1.
Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
8. ROR1 expression is not a unique marker of CLL.
Barna G; Mihalik R; Timár B; Tömböl J; Csende Z; Sebestyén A; Bödör C; Csernus B; Reiniger L; Peták I; Matolcsy A
Hematol Oncol; 2011 Mar; 29(1):17-21. PubMed ID: 20597086
[TBL] [Abstract][Full Text] [Related]
9. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
Fukuda T; Chen L; Endo T; Tang L; Lu D; Castro JE; Widhopf GF; Rassenti LZ; Cantwell MJ; Prussak CE; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3047-52. PubMed ID: 18287027
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia.
Shabani M; Asgarian-Omran H; Jeddi-Tehrani M; Vossough P; Faranoush M; Sharifian RA; Toughe GR; Kordmahin M; Khoshnoodi J; Roohi A; Tavoosi N; Mellstedt H; Rabbani H; Shokri F
Tumour Biol; 2007; 28(6):318-26. PubMed ID: 18354269
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.
Choi MY; Widhopf GF; Wu CC; Cui B; Lao F; Sadarangani A; Cavagnaro J; Prussak C; Carson DA; Jamieson C; Kipps TJ
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S167-9. PubMed ID: 26297272
[TBL] [Abstract][Full Text] [Related]
12. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
PLoS One; 2013; 8(10):e78339. PubMed ID: 24205204
[TBL] [Abstract][Full Text] [Related]
14.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
15. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.
Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Br J Haematol; 2010 Nov; 151(4):327-35. PubMed ID: 20813009
[TBL] [Abstract][Full Text] [Related]
16. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
17. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
[TBL] [Abstract][Full Text] [Related]
18. Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.
Leung CS
J Immunol Res; 2018; 2018():2480931. PubMed ID: 29850623
[TBL] [Abstract][Full Text] [Related]
19. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
[TBL] [Abstract][Full Text] [Related]
20. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Leuk Lymphoma; 2013 Apr; 54(4):843-50. PubMed ID: 22988987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
